Gender and interindividual variability in pharmacokinetics

Drug Metabolism Reviews

Volumn 41, Issue 3, 2009, Pages 408-421

  Nicolas, Jean Marie ^a   Espie, Pascal ^a   Molimard, Mathieu ^b  

^a UCB PHARMA   (Belgium)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Antihistamines; Cytochrome P 450; Food; Gender; Genetic polymorphism; Hormonal effect; Transporters; Variability

Indexed keywords

ANTIALLERGIC AGENT; ANTIARRHYTHMIC AGENT; ANTIMALARIAL AGENT; ASTEMIZOLE; BROMPHENIRAMINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CLEMASTINE; CYCLOSPORIN; CYPROHEPTADINE; DESLORATADINE; DIAZEPAM; DIPHENHYDRAMINE; DOXYLAMINE; GASTROINTESTINAL AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; LEVOCETIRIZINE; LIDOCAINE; LORATADINE; MIDAZOLAM; MIRTAZAPINE; MIZOLASTINE; NEUROLEPTIC AGENT; NIFEDIPINE; OLANZAPINE; PROPANOL; TERFENADINE; UNINDEXED DRUG; CARRIER PROTEIN; CYTOCHROME P450;

ALLERGIC RHINITIS; ALLERGY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; EATING HABIT; ENVIRONMENTAL FACTOR; ENZYME METABOLISM; GENETIC POLYMORPHISM; HORMONE ACTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW; SEDATION; SEX DIFFERENCE; SIDE EFFECT; TORSADE DES POINTES; TRANSPORT KINETICS; UNSPECIFIED SIDE EFFECT; URTICARIA; BLOOD; CHEMICALLY INDUCED DISORDER; DIET; DRUG DETOXIFICATION; FEMALE; GENETICS; MALE; METABOLISM; SEXUAL DEVELOPMENT; SMOKING; TISSUE DISTRIBUTION;

ANTI-ALLERGIC AGENTS; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DIET; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; SMOKING; TISSUE DISTRIBUTION; TORSADES DE POINTES;

EID: 73449141860     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/10837450902891485     Document Type: Review

References (149)

1. Anderson, G.D. (2005). Sex and racial diferences in pharmacological response: where is the evidence? Pharmacogenetics, pharma-cokinetics, and pharmacodynamics. J Womens Health 14:19-29.
2. Armstrong, S.C., Cozza, K.L. (2003). Antihistamines. Psychosomatics 44:430-434.
3. Ayrton, A., Morgan, P. (2001). Role of transport proteins in drug absorption, distribution, and excretion. Xenobiotica 31:469-497.
4. Baltes, B., Coupez, R., Giezek, H., Voss, G., Meyerhof, C., Strolin Benedetti, M. (2001). Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 15:269-277.
5. Barr, J., Donner, A. (1995). Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin 11:827-1487
6. Barrenäs, F., Andersson, B., Cardell, L.O., Langston, M., Mobini, R., Perkins, A., et al. (2008). Gender diferences in infammatory proteins and pathways in seasonal allergic rhinitis. Cytokine 42:325-329.
7. Beierle, I., Meibohm, B., Derendorf, H. (1999). Gender diferences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ter 37:529-547.
8. Benedek, I.H., Blouin, R.A., McNamara, P.J. (1984). Infuence of smoking on serum protein composition and the protein binding of drugs. J Pharm Pharmacol 36:214-216.
9. Berg, U.B. (2006). Diferences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transpl 21:2577-2582.
10. Berlanga, C., Flores-Ramos, M. (2006). Diferent gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efcacy of citalopram and reboxetine. J Afect Disord 95:119-123.
11. Bigos, K.L., Pollock, B.G., Coley, K.C., Miller del, D., Marder, S.R., Aravagiri, M., et al. (2008). Sex, race, and smoking impact olan-zapine exposure. J Clin Pharmacol 48:157-165.
12. Bonhomme-Faivre, L., Devocelle, A., Saliba, F., Chatled, S., Maccario, J., Farinotti, R., et al. (2004). MDR-1 C3435T polymorphism infuences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 78:21-25.
13. Bracco, D., Landry, C., Dubois, M.J., Eggimann, P. (2008). Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 34:791-796.
14. Burstein, A.H., Reiss, W.G., Kantor, E., Anderson, G.D. (1998). Cytochrome P450 3A4 activity in premenopausal and post-menopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Pharmacotherapy 18:1271-1276.
15. Chao, S.T., Prather, D., Pinson, D., Coen, P., Pruitt, B., Knowles, M., et al. (1991). Efect of food on bioavailability of pseudoephe-drine and brompheniramine administered from a gastrointestinal therapeutic system. J Pharm Sci 80:432-435.
16. Chiou, W.L., Chung, S.M., Wu, T.C. (2000). Potential role of P-glycoprotein in afecting hepatic metabolism of drugs. Pharm Res 17:903-905.
17. Chowbay, B., Cumaraswamy, S., Cheung, Y., Zhou, Q., Lee, E. (2003). Genetic polymorphisms in MDR1 and CY3A4 genes in Asians and the infuence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95.
18. Ciccone, G.K., Holdcroft, A. (1999). Drugs and sex diferences: a review of drugs relating to anaesthesia. Br J Anaesth 82:255-265.
19. Cohen, M., Panagides, J., Timmer, C.J., Huisman, J.A. (1997). Pharmacokinetics of mirtazapine from orally administered tablets: infuence of a high-fat meal. Eur J Drug Metab Pharmacokinet 22:103-110.
20. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R., Kim, R.B. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
21. Dadashzadeh, S., Javadian, B., Sadeghian, S. (2006). Te efect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 27:329-334.
22. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R.J., Mohrenweiser, H.W., et al. (2001). Identifcation of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ter 299:825-831.
23. Davis, M. (2005). Gender diferences in P-glycoprotein: drug toxicity and response. J Clin Oncol 23:6439-6440.
24. Dekhuijzen, P.N., Koopmans, P.P. (2002). Pharmacokinetic profle of zafrlukast. Clin Pharmacokinet 41:105-114
25. DeNardo, G., Yuan, A., Goldstein, D., Richman, C., O'Donnell, R., Shen, S., et al. (2003). Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiola-beled MAbs. Cancer Biother Radiopharm 18:231-237.
26. Denton, T.T., Zhang, X., Cashman, J.R. (2004). Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 67:751-756.
27. Desai, H.D., Seabolt, J., Jann, M.W. (2001). Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 15:469-494.
28. Doki, K., Homma, M., Kuga, K., Aonuma, K., Sakai, S., Yamaguchi, I., et al. (2007). Gender-associated diferences in pharmacokinet-ics and anti-arrhythmic efects of fecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 63:951-957.
29. Drescher, S., Schaefeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., et al. (2002). MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526-534.
30. Dresser, G.K., Schwarz, U.I., Wilkinson, G.R., Kim, R.B., Roden, D.M. (2001). Fexofenadine bioavailability modulated by dietary salt. Clin Pharmacol Ter 69:23.
31. Drici, M.D., Clément, N. (2001). Is gender a risk factor for adverse drug reactions? Te example of drug-induced long QT syndrome. Drug Saf 24:575-585.
32. DuBuske, L. (2007). Desloratadine for chronic idiopathic urticaria: a review of clinical efcacy. Am J Clin Dermatol 8:271-283.
33. Dumez, H., Guetens, G., De Boeck, G., Highley, M.S., de Bruijn, E.A., van Oosterom, A.T., et al. (2005). In vitro partition of irinotecan (CPT-11) in human volunteer blood: the infuence of concentration, gender, and smoking. Anti-Cancer Drugs 16:893-895. (Pubitemid 41215756)
34. Ebert, S.N., Liu, X.K., Woosley, R.L. (1998). Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7:547-557.
35. Eiselt, R., Domanski, T.L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., et al. (2001). Identifcation and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
36. El Desoky, E.S., Derendorf, H., Klotz, U. (2006). Variability in response to cardiovascular drugs. Curr Clin Pharmacol 1:35-46.
37. Ernstgård, L., Sjögren, B., Warholm, M., Johanson, G. (2003). Sex diferences in the toxicokinetics of inhaled solvent vapors in humans 2.2-propanol. Toxicol Appl Pharmacol 193:158-167. (Pubitemid 37479324)
38. Faber, K.N., Müller, M., Jansen, P.L.M. (2003). Drug transport proteins in the liver. Adv Drug Deliv Rev 55:107-124.
39. Feldman, M., Richardson, C.T., Walsh, J.H. (1983). Sex-related difer-ences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest 71:715-720.
40. Fisher, M.M., Yousef, I.M. (1973). Sex diferences in the bile acid composition of human bile: studies in patients with and without gallstones. Can Med Assoc J 109:190-193.
41. Flexner, C. (2008). Pharmacoecology: a new name for an old science. Clin Pharmacol Ter 83:375-379.
42. Food and Drug Administration, Center for Drug Evaluation and Research. (2002). Guidance for Industry Food-Efect Bioavailability and Fed Bioequivalence Studies. Silver Spring, Maryland, USA: U.S. Food and Drug Administration.
43. Frick, G.S., Blum, R.A., Kovacs, S.J., Vitow, C., Stewart, J.A., Kraft, W.K. (2004). Prevalence of the slow metabolizer (SM) phenotype and single-dose pharmacokinetics (PK) of desloratadine (DCL) in a population of healthy adults. Clin Pharmacol Ter 75:P9.
44. Fromm, M.F., Darbar, D., Dell'Orto, S., Roden, D.M. (1999). Modulation of efect of dietary salt on prehepatic frst-pass metabolism: efects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ter 290:253-258.
45. Gandhi, M., Aweeka, F., Greenblatt, R.M., Blaschke, T.F. (2004). Sex diferences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499-523.
46. Gerlof, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., et al. (2002). MDR1 genotypes do not infuence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharm 54:610-616.
47. Gervasini, G., Vizcaino, S., Carrillo, J.A., Caballero, M.J., Benitez, J. (2006). Te efect of CYP2J2, CYP3A4, CYP3A5, and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 62:177-186.
48. Gorski, J.C., Vannaprasaht, S., Hamman, M.A., Ambrosius, W.T., Bruce, M.A., Haehner-Daniels, B., et al. (2003). Te efect of age, sex, and rifampin administration on intestinal and hepatic cyto-chrome P450 3A activity. Clin Pharmacol Ter 74:275-287.
49. Goryachkina, K., Burbello, A., Boldueva, S., Babak, S., Bergman, U., Bertilsson, L. (2008). CYP2D6 is a major determinant of metoprolol disposition and efects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 64:1163-1173.
50. Gotoh, Y., Kato, Y., Stieger, B., Meier, P.J., Sugiyama, Y. (2002). Gender diference in the Oatp1-mediated tubular reabsorption of estra-diol 17-beta-D-glucuronide in rats. Am J Physiol Endocrinol Metab 282:1245-1254.
51. Greenblatt, D.J., Allen, M.D., Harmatz, J.S., Shader, R.I. (1980). Diazepam disposition determinants. Clin Pharmacol Ter 27:301-312.
52. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., von Richter, O., Zundler, J., et al. (1999). Te role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
53. Groves, C.E., Suhre, W.B., Cherrington, N.J., Wright, S.H. (2006). Sex diferences in the mRNA, protein, and functional expression of organic anion transporter (Oat). 1, Oat3, and organic cation transporter (Oct). 2 in rabbit renal proximal tubules. J Pharmacol Exp Ter 316:743-752.
54. Hägg, S., Spigset, O., Dahlqvist, R. (2001). Infuence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173.
55. Haji-Momenian, S., Rieger, J.M., Macdonald, T.L., Brown, M.L. (2003). Comparative molecular feld analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem 11:5545-5554.
56. Hanks, G.W., Reid, C. (2005). Contribution to variability in response to opioids. Supp Care Cancer 13:145-152.
57. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fuji, T., Miyazaki, H., et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ter 300:298-304.
58. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L., Karlsson, J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
59. Hinds, D., Stuve, L., Nilsen, G., Halperin, E., Eskin, E., Ballinger, D.G., et al. (2005). Whole-genome patterns of common DNA variation in three human populations. Science 307:1072-1079.
60. Hofmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmöller, J., Johne, A., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
61. Hreiche, R., Morissette, P., Turgeon, J. (2008). Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 5:124-135.
62. Hunt, C.M., Westerkam, W.R., Stave, G.M., Wilson, J.A. (1992). Hepatic cytochrome P-4503A (CYP3A). activity in the elderly. Mech Ageing Dev 64:189-199.
63. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.Q., Klein, K., Nuessler, A.C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brochmöler, J., Halpert, J.R., Zanger, U.M., Wojnowshi, L. (2001). Te genetic determinants of the CYP3A5 polymorphism. Pharmacogenitics. 11:773-779
64. Ieiri, I., Takane, H., Hirota, T., Otsubo, K., Higuchi, S. (2006). Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Exp Opin Drug Metab Toxicol 2:651-674.
65. 1- antagonist epinastine across the blood-brain barrier. Drug Metab Dispos 32:519-524.
66. Jafe, C.A., Turgeon, D.K., Lown, K., Demott-Friberg, R., Watkins, P.B. (2002). Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab 283:1008-1015.
67. Johne, A., Köpke, K., Gerlof, T., Mai, I., Rietbrock, S., Meisel, C., et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ter 72:584-594.
68. Kahan, B.D., Kramer, W.G., Wideman, C., Flechner, S.M., Lorber, M.I., Van Buren, CT. (1986). Demographic factors afecting the phar-macokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41:459-464.
69. Kane, G.C., Lipsky, J.J. (2000). Drug-grapefruit juice interactions. Mayo Clin Proc 75:933-942.
70. Keshava, C., McCanlies, E.C., Weston, A. (2004). CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 160:825-841.
71. Kharasch, E.D., Mautz, D., Senn, T., Lentz, G., Cox, K. (1999). Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 39:275-280.
72. Kharasch, E.D., Russell, M., Garton, K., Lentz, G., Bowdle, T.A., Cox, K. (1997). Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 87:26-35.
73. Kim, R. (2000). Transporters in drug disposition. Curr Opin Drug Discov Devel 3:94-101.
74. Kim, R., Kim, W.Y., Benet, L.Z. (2004). P-glycoprotein (P-gp/MDR1).-mediated efux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 21:1284-1293.
75. Kim, R.B., Leake, B.F., Choo, E.F., Dresser, G.K., Kubba, S.V., Schwarz, U.I., et al. (2001). Identifcation of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ter 70:189-199.
76. Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., et al. (2002). Interindividual variability and tissue-specifcity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos 30:1108-1114.
77. Krecic-Shepard, M.E., Park, K., Barnas, C., Slimko, J., Kerwin, D.R., Schwartz, J.B. (2000). Race and sex infuence clearance of nifedipine: results of a population study. Clin Pharmacol Ter 68:130-142.
78. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
79. Labbé, L., Sirois, C., Pilote, S., Arseneault, M., Robitaille, N.M., Turgeon, J., et al. (2000). Efect of gender, sex hormones, time variables, and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425-438.
80. Lamba, J.K., Lin, Y.S., Schuetz, E.G., Tummel, K.E. (2002a). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
81. Lamba, J.K., Lin, Y.S., Tummel, K., Daly, A., Watkins, P.B., Strom, S., et al. (2002b). Common allelic variants of cytochrome P4503A4 and their prevalence in diferent populations. Pharmacogenetics 12:121-132.
82. Lasseter, K.C., Dilzer, S.C., Vargas, R., Waldman, S., Noveck, R.J. (2004). Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet 43:121-129.
83. Lovern, M., Sargentini-Maier, M-L., Otoul, C., Watelet, J-B. (2009) Population Pharmacokinetic and Pharmacodynamic analysis in allergic diseases. Drug Metabolism Reviews (41).
84. Luner, P.E., Babu, S.R., Radebaugh, G.W. (1994). Te efects of bile salts and lipids on the physicochemical behavior of gemfbrozil. Pharm Res 11:1755-1760.
85. Mahar Doan, K.M., Wring, S.A., Shampine, L.J., Jordan, K.H., Bishop, J.P., Kratz, J., et al. (2004). Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efux, and plasma protein binding. Pharmacology 72:92-98.
86. Mahar Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh, C.J., et al. (2002). Passive permeability and P-glycoprotein-mediated efux diferentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ter 303:1029-1037.
87. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D., Lehmann, M.H. (1993). Female gender as a risk factor for tor-sades de pointes associated with cardiovascular drugs. JAMA 270:2590-2597.
88. Matzke, G.R., Halstenson, C.E., Opsahl, J.A., Hilbert, J., Perentesis, G., Radwanski, E., et al. (1990). Pharmacokinetics of loratadine in patients with renal insufciency. J Clin Pharmacol 30:364-371.
89. McCune, J.S., Lindley, C., Decker, J.L., Williamson, K.M., Meadowcroft, A.M., Graf, D., et al. (2001). Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723-731.
90. Meibohm, B., Beierle, I., Derendorf, H. (2002). How important are gender diferences in pharmacokinetics? Clin Pharmacokinet 41:329-342.
91. Mentré, F., Dubruc, C., Ténot, J.P. (2001). Population pharmacokinetic analysis and optimization of the experimental design for mizolas-tine solution in children. J Pharmacokinet Biopharm 28:299-319.
92. Mesnil, F., Mentré, F., Dubruc, C., Ténot, J.P., Mallet, A. (1998). Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the Nonparametric maximum likelihood method. J. Pharmacokinet Biopharm 26:133-161.
93. Min, D., Ellingrod, V. (2002). C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ter Drug Monit 24:400-404.
94. Molimard, M., Diquet, B., Benedetti, M.S. (2004). Comparison of pharmacokinetics and metabolism of desloratadine, fexofena-dine, levocetirizine, and mizolastine in humans. Fundam Clin Pharmacol 18:399-411.
95. Nettles, R.E., Kiefer, T.L., Parsons, T., Johnson, J., Cofrancesco, J., Jr, Gallant, J.E., et al. (2006). Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 42:1189-1196.
96. Niemi, M., Kivistö, K., Hofmann, U., Schwab, M., Eichelbaum, M., Fromm, M. (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602-604. (Pubitemid 40632253)
97. Nomeir, A.A., Mojaverian, P., Kosoglou, T., Afrime, M.B., Nezamis, J., Rodwanski, E., et al. (1996). Infuence of food on the oral bio-availability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers. J Clin Pharmacol 36:923-930.
98. Obradovic, T., Dobson, G.G., Shingaki, T., Kungu, T., Hidalgo, I.J. (2007). Assessment of the frst-and second-generation antihis-tamines brain penetration and role of P-glycoprotein. Pharm Res 24:318-327.
99. Ohashi, R., Kamikozawa, Y., Sugiura, M., Fukuda, H., Yabuuchi, H., Tamai, I. (2006). Efect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 34:793-799.
100. Oryszczyn, M.P., Bouzigon, E., Maccario, J., Siroux, V., Nadif, R., Wright, A., et al. (2007). Interrelationships of quantitative asthma-related phenotypes in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy. J Allergy Clin Immunol 119:57-63.
101. Paine, M.F., Ludington, S.S., Chen, M.L., Stewart, P.W., Huang, S.M., Watkins, P.B. (2005). Do men and women difer in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33:426-433.
102. Pang, K.S. (2003). Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507-1519.
103. Parkinson, A., Mudra, D.R., Johnson, C., Dwyer, A., Carroll, K.M. (2004). Te efects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver micro-somes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
104. Passalacqua, G., Canonica, G.W. (2005). A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis Clin Ter 27:979-992.
105. Pentikis, H.S., Huang, M.Y., Dorr, M.B., Heald, D.L. (1997). Te efect of food on the bioavailability of ebastine. Am J Ter 4:80-84.
106. Pleym, H., Spigset, O., Kharasch, E.D., Dale, O. (2003). Gender differences in drug efects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241-259.
107. Pollock, B.G. (1997). Gender diferences in psychotropic drug metabolism. Psychopharmacol Bull 33:235-241.
108. Prenner, B., Kim, K., Gupta, S., Khalilieh, S., Kantesaria, B., Manitpisitkul, P., et al. (2006). Adult and paediatric poor metab-olisers of desloratadine: an assessment of pharmacokinetics and safety. Exp Opin Drug Saf 5:211-223.
109. Ragette, R., Kamler, M., Weinreich, G., Teschler, H., Jakob, H. (2005). Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transpl 24:1315-1319.
110. Ramanathan, R., Reyderman, L., Su, A.D., Alvarez, N., Chowdhury, S.K., Alton, K.B., et al. (2007). Disposition of desloratadine in healthy volunteers. Xenobiotica 37:770-787.
111. Renwick, A.G. (1999). Te metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 29(Suppl 3):116-124.
112. Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., et al. (2001). MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400-1404.
113. Salokangas, R.K., Saarijarvi, S., Taiminen, T., Lehto, H., Niemi, H., Ahola, V., et al. (1997). Efect of smoking on neuroleptics in schizophrenia. Schizophr Res 23: 55-60.
114. 1-receptor antagonist, in adults and children. Br J Clin Pharmacol 59:43-53.
115. 1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 62:995-1001.
116. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W., et al. (2000). CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ter 67:48-56
117. Schmucker, D.L., Woodhouse, K.W., Wang, R.K., Wynne, H., James, O.F., McManus, M., et al. (1990). Efects of age and gender on in vitro properties of human liver microsomal monooxygenases Clin Pharmacol Ter 48:365-374.
118. Schran, H.F., Petryk, L., Chang, C.T., O'Connor, R., Gelbert, M.B. (1996). Te pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol 36:911-922.
119. Schuetz, E.G., Furuya, K.N., Schuetz, J.D. (1995). Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ter 275:1011-1018.
120. Schwab, M., Eichelbaum, M., Fromm, M. (2003). Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307. (Pubitemid 37372643)
121. Schwartz, J.B. (2003). Te infuence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-121.
122. Sharma, A., Hamelin, B.A. (2003). Classic Histamine H1 Receptor Antagonists: A Critical Review of their Metabolic and Pharmacokinetic Fate from a Bird's Eye View. Current Drug Metabolism. 4:105-129.
123. Shon, J., Chun, H., Kim, K., Kim, E., Yoon, Y., Jang, I., et al. (2002). Te PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects. Clin Pharmacol Ter 71:P71. [poster abstract]
124. Siegsmund, M., Brinkmann, U., Scháfeler, E., Weirich, G., Schwab, M., Eichelbaum, M., et al. (2002). Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847-1854.
125. Sim, S.C., Edwards, R.J., Boobis, A.R., Ingelman-Sundberg, M. (2005). CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 15:625-631.
126. Solans, A., Carbó, M.L., Peña, J., Nadal, T., Izquierdo, I., Merlos, M. (2007). Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther 29:900-908.
127. Spina, S.P., Ensom, M.H. (2007). Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27:389-398.
128. Stoltz, M., Arumugham, T., Lippert, C., Yu, D., Bhargava, V., Eller, M., et al. (1997). Efect of food on the bioavailability of fexofena-dine hydrochloride (MDL 16455A). Biopharm Drug Dispos 18:645-648.
129. Suzuki, T., Zhao, Y.L., Nadai, M., Naruhashi, K., Shimizu, A., Takagi, K., et al. (2006). Gender-related diferences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 79:455-461.
130. Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., et al. (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ter 297:1137-1143.
131. Tanaka, Y., Fujiwara, T., Esumi, Y. (1992). Sex diference in the excretion of zenarestat in mice, rats, dogs, and humans. Xenobiotica 22:941-947.
132. Tang, K., Ngoi, S., Gwee, P., Chua, J., Lee, E., Chong, S., et al. (2002). Distinct haplotype profles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437-450.
133. Timmer, C.J., Sitsen, J.M., Delbressine, L.P. (2000). Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461-474.
134. Undevia, S.D., Gomez-Abuin, G., Ratain, M.J. (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5:447-458.
135. Vacher, V., Wu, C., Benet, L. (1995). Overlapping substrate spe-cifcity and tissue distribution of cytochrome P4503A4 and P-glycoprotein: implication for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
136. Vermeeren, A., Ramaekers, J.G., O'Hanlon, J.F. (2002). Efects of eme-dastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 16:57-64.
137. Verster, J.C., Volkerts, E.R. (2004). Antihistamines and driving ability: evidence from on-the-road driving studies during normal traf-fc. Ann Allergy Asthma Immunol 92:294-303.
138. von Ahsen, N., Richter, M., Grupp, C., Ringe, B., Oellerich, M., Armstrong, V.W. (2001). No infuence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048-1052.
139. Watkins, P. (1997). Te barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
140. White, H.D., Barbash, G.I., Modan, M., Simes, J., Diaz, R., Hampton, J.R., et al. (1993). After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation 88:2097-2103.
141. Whitfeld, P.F., Hobsley, M. (1987). Comparison of maximal gastric secretion in smokers and nonsmokers with and without duodenal ulcer. Gut 28:557-560. (Pubitemid 17073221)
142. Wojnowski, L., Kamdem, L.K. (2006). Clinical implications of CYP3A polymorphisms. Exp Opin Drug Metab Toxicol 2:171-182.
143. Wolbold, R., Klein, K., Burk, O., Nüssler, A.K., Neuhaus, P., Eichelbaum, M., et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
144. Wong, L.T., Sitar, D.S., Aoki, F.Y. (1995). Chronic tobacco smoking and gender as variables afecting amantadine disposition in healthy subjects. Br J Clin Pharmacol 39:81-84.
145. Yates, C., Zhang, W., Song, P., Li, S., Gaber, A., Kotb, M., et al. (2003). Te efect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43:555-564.
146. Yi, S.Y., Hong, K.S., Lim, H.S., Chung, J.Y., Oh, D.S., Kim, J.R., Jung, H.R., Cho, J.Y., Yu, K.S., Jang, I.J., Shin, S.G. (2004). A variant 2677A allele of the MDR1 gene afects fexofenadine disposition. Clin Pharmacol Ter. 76:418-427
147. Yin, O.Q., Shi, X.J., Tomlinson, B., Chow, M.S. (2005). Efect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos 33:1283-1287.
148. Zevin, S., Benowitz, N.L. (1999). Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36:425-438.
149. Zhang, J., Kuehl, P., Green, E., Touchman, J., Watkins, P., Daly, A., et al. (2001). Te human pregnane X receptor: genomic structure and identifcation and functional characterization of of natural allelic variants. Pharmacogenetics 11:555-572.